Establishment of a drug sensitivity panel using human lung cancer cell lines

Acta Medica Okayama

Volumn 53, Issue 2, 1999, Pages 67-75

  Matsushita, Akio ^a   Tabata, Masahiro ^a   Ueoka, Hiroshi ^a   Kiura, Katsuyuki ^a   Shibayama, Takuo ^a   Aoe, Keisuke ^a   Kohara, Hiroyuki ^a   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Drug resistance; Drug screening system; Lung cancer cell line; MTT assay

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CELL CULTURE; CLUSTER ANALYSIS; HUMAN; LUNG TUMOR; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CLUSTER ANALYSIS; HUMANS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033111956     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kuroishi T, Hirose K, Tominaga S, Ogawa H and Tajima K: Prediction of future cancer mortality in Japan. Jpn J Clin Oncol (1992) 22, 365 -369.
2. Hoel DG, Davis DL, Miller AB, Sondik EJ and Swerdlow AJ: Trends in cancer mortality in 15 industrialized countries, 1969-1986. J Natl Cancer Inst (1992) 84, 313-320.
3. Aisner J: Extensive-disease small-cell lung cancer: The thrill of victory; The agony of defeat. J Clin Oncol (1996) 14, 658-665.
4. Sandler AB: Current management of small cell lung cancer. Semin Oncol (1997) 24, 463-476.
5. Ramanathan RK and Belani CP: Chemotherapy for advanced non-small cell lung cancer: Past, present, and future. Semin Oncol (1997) 24, 440-454.
6. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M and Suemasu K: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst (1991) 83, 855-861.
7. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO, Omura GA and Greco FA: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol (1992) 10, 282-291.
8. Furuse K, Kubota K, Nishiwaki Y, Takada M, Kurita Y, Watanabe K, Noda K, Fukuoka M, Ariyoshi H, Osaki Y, Tamura H and Saijo N: Phase III study of dose intensive weekly chemotherapy with recombinant human granulocyte-colony stimulating factor (G-CSF) versus standard chemotherapy in extensive stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol (1996) 15, 375.
9. Murray M, Livingston R, Shepherd F, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin J, Grafton C, Turris A, Walde D, Croft H and Ottaway J: A randomized study CODE plus thoracic irradiation versus alternating CAV/EP for extensive stage small cell lung cancer (ESCLC). Proc Am Soc Clin Oncol (1997) 16, 456a.
10. Watanabe Y: Experimental model of human lung cancer. Part I. Establishment and characterization of new tissue culture cell lines from human squamous cell carcinoma and adenocarcinoma of the lung. Okayama Igakkai Zasshi (1985) 97, 691-700 (in Japanese).
11. Kishimoto N: Studies on cell biology and chemotherapy of lung cancer using tissue culture techniques Part 2. Biological characteristics of five newly established small cell lung cancer cell lines. Okayama Igakkai Zasshi (1992) 104, 905-913 (in Japanese).
12. Kiura K, Watarai S, Shibayama T, Ohnoshi T, Kimura I and Yasuda T: Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines. Anti-Cancer Drug Des (1993) 8, 417-428.
13. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 65, 55-63.
14. Takigawa N, Ohnoshi T, Ueoka H, Kiura K and Kimura I: Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama (1992) 46, 203-212.
15. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J and Boyd MR: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 81, 1088-1092.
16. Ward Jr JH: Hierarchical grouping to optimize an objective function. J Am Stat Assoc (1963) 58, 236-44.
17. Grant SC, Gralla RJ, Kris MG, Orazem J and Kitsis EA: Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: The case for studies in previously treated patients. J Clin Oncol (1992) 10, 484 -498.
18. Bakowski MT and Crouch JC: Chemotherapy of non-small cell lung cancer: A reappraisal and a look to the future. Cancer Treat Rev (1983) 10, 159-173.
19. Rowinsky EK and Ettinger DS: Drug development and new drugs for lung cancer; in Lung Cancer; Principles and Practice, Pass HI, Mitchell JB, Johnson DH and Turrisi AT eds, Lippincot-Raven Publishers, Philadelphia (1996) pp793-810.
20. Bai R, Pettit GR and Hamel E: Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem (1990) 265, 17141-17149.
21. Tsuruo T, Oh-hara T, Iida H, Tsukagoshi S, Sato Z, Matsuda I, Iwasaki S, Okuda S, Shimizu F, Sasagawa K, Fukami M and Fukuda K: Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res (1986) 46, 381-385.
22. Goldie JH, Coldman AJ and Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep (1982) 66, 439-449.
23. Le Chevalier TL, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P and Tursz T: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol (1994) 12, 360-367.
24. Ruckdeschel JC, Carney DN, Oie HK, Russell EK and Gazdar AF: In vitro chemosensitivity of human lung cancer cell lines. Cancer Treat Rep (1987) 71, 697-704.
25. Van Kalken CK, Pinedo HM and Giaccone G: Multidrug resistance from the clinical point of view. Eur J Cancer (1991) 27, 1481-1486.